SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%
Zynerba Positive Autism Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 10小时前
The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight
Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few FDA approvals.
Benzinga · 1天前
Stocks To Watch: Warner Music, Cisco, Casinos And Cars
Seeking Alpha - Article · 1天前
Informative Insider Purchasing Activity - Weekly Update (05/22/20-05/29/20)
Seeking Alpha - Article · 1天前
Is Pfizer a Great Dividend Stock?
MotleyFool.com · 1天前
Gilead Continues to Build Cancer Franchise
GuruFocus.com · 1天前
FDA OKs AbbVie med for women with fibroid-related issues
The FDA approves AbbVie's (ABBV -0.0%) Oriahnn (elagolix, estradiol and norethindrone acetate) capsules (co-packaged for oral use) for the management of he
seekingalpha · 1天前
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
PR Newswire · 1天前
These stocks are hated the most by hedge funds
Here are the most shorted stocks by hedge funds including AbbVie, Tesla and Teladoc Health.
CNBC.com · 2天前
10 Of 65 S&P 500 Aristocrat June Dogs Are Ready To Run Forever
Seeking Alpha - Article · 2天前
Ironwood to Halt MD-7246 Development After Study Failure
Zacks · 3天前
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
Zacks · 3天前
Top 1st-Quarter Buys of Steven Cohen's Firm
GuruFocus.com · 3天前
Ironwood Pharma's MD-7246 flunks mid-stage study in IBS-D
A Phase II trial evaluating Ironwood Pharmaceuticals' (NASDAQ:IRWD) MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome
seekingalpha · 3天前
Point72 Asset Management Buys Micron Technology, Baxter
GuruFocus.com · 3天前
Top Ranked Income Stocks to Buy for May 27th
Zacks · 4天前
AbbVie, Ironwood to discontinue experimental IBS drug
MarketWatch · 4天前
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
PR Newswire · 4天前
Don't Gamble In The Markets, Look At These 2 Blue Chip Healthcare Names Instead
Seeking Alpha - Article · 4天前
Is Coherus BioSciences a Buy?
MotleyFool.com · 4天前